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Circulating microRNAs in breast cancer: novel
diagnostic and prognostic biomarkers
Rimi Hamam1, Dana Hamam1,2, Khalid A Alsaleh3, Moustapha Kassem1,4,5, Waleed Zaher6,7, Musaad Alfayez1, Abdullah Aldahmash1,8
and Nehad M Alajez*,1
Effective management of breast cancer depends on early diagnosis and proper monitoring of patients’ response to therapy.
However, these goals are difficult to achieve because of the lack of sensitive and specific biomarkers for early detection and for
disease monitoring. Accumulating evidence in the past several years has highlighted the potential use of peripheral blood
circulating nucleic acids such as DNA, mRNA and micro (mi)RNA in breast cancer diagnosis, prognosis and for monitoring
response to anticancer therapy. Among these, circulating miRNA is increasingly recognized as a promising biomarker, given the
ease with which miRNAs can be isolated and their structural stability under different conditions of sample processing and
isolation. In this review, we provide current state-of-the-art of miRNA biogenesis, function and discuss the advantages, limitations,
as well as pitfalls of using circulating miRNAs as diagnostic, prognostic or predictive biomarkers in breast cancer management.
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Facts
 Micro (mi)RNAs are small RNA species whose expression
is often dysregulated in cancer.
 MiRNAs are present in the circulation of cancer patients
and can potentially be used for disease monitoring.
 Large proportion of circulating miRNAs in cancer patients
do not originate from tumors but rather reflect the body’s
homeostatic response.
Open Questions
 Are circulating miRNAs disease specific?
 What is the best approach for sample processing and
detection of circulating miRNAs in breast cancer patients?
 What is the best normalization approach when quantifying
circulating miRNAs?
Breast cancer is one of the most commonmalignant diseases in
theworld, with an estimated 1.5million new cases per year.1 The
incidence has been decreasing in the developed world;2
however, it remains a common cause of death in the USA and
UK; Caucasian women have an estimated lifetime risk of 1 in 9.3
There are numerous risk factors for breast cancer, including
age, family history, obesity and exposure to hormones and
therapeutic radiation.4 Models used to estimate breast cancer
risk vary depending on population characteristics; however,
with the exception of hormone prophylaxis, such models are
not suitable for individual patient management. The two most
common types of breast cancer are ductal and lobular
carcinoma. An important issue for treatment is selecting the
right therapeutic modality, which is largely dependent on
disease subtype. Breast cancer is currently molecularly
classified based on expression of sex hormone receptors
and human epidermal growth factor receptor (HER)2, which
can determine diagnostic approach and treatment choice.5
However, other methods of classification that are based on
global gene expression are gaining momentum.6 Molecular
data – for instance, from oncotype DX breast cancer assays in
lymph node-negative breast cancer – have increased our
understanding of the mechanisms of chemotherapy and
hormone resistance, such as the role of mutations in estrogen
receptor (ER)1 in resistance to endocrine therapy.7
Micro (mi)RNAs
MiRNAs are short, single-stranded RNA sequences (usually
19–23 nucleotides (nts)) derived from ~70-nt precursors that
control gene expression in a variety of physiological and
developmental processes, thus having a critical role in post-
transcriptional regulation of gene expression in a broad range
of biological systems.8–11 In humans, a single miRNA has
several dozens or even hundreds of mRNA targets. Over 60%
of human protein-coding genes are predicted to contain
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miRNA-binding sites in their 3′-untranslated region (3′-
UTR).12 According to the miRBase database (www.mirbase.
org), there are 42500 mature miRNA sequences in the
human genome.13,14 MiRNAsmediate the repression of target
mRNAs by base paring to complementary sequences in the
3′-UTR, causing transcript destabilization, translational
repression or both15 (Figure 1). Recent studies have reported
that miRNAs also modulate gene expression by binding to
other regions, including protein-coding exons,16–18 and can
even induce gene expression in mammalian cells.19
MiRNA Biogenesis and Maturation
The biogenesis of mature miRNA involves a series of biological
processes (Figure 1), for review see Winter et al.20 A primary
miRNA transcript (pri-miRNA) is first transcribed in the nucleus
by RNA polymerase II (or sometime by RNA polymerase III),
which is subsequently cleaved by Drosha into a 70-nt known as
precursor miRNA (pre-miRNA).21–23 The pre-miRNA is
exported from the nucleus to the cytoplasm by exportin-524,25
and loaded onto Dicer; the loop is then cleaved, producing a
double-stranded structure composed of miRNA and antisense
miRNA*.26 The latter is usually degraded, whereas the long
(~22 nt) mature miRNA strand is incorporated into the miRNA-
induced silencing complex,27,28 leading to gene silencing via
mRNA cleavage or translational repression depending on the
degree of complementarity between the miRNA and target
mRNA transcript29–32 (Figure 1). It was recently reported that
miRNAs can switch from translational repression to induction.19
Figure 1 Schema depicting miRNA biogenesis and function. Primary miRNA transcript (pri-miRNA) is transcribed by RNA polymerase II/III in the nucleus, forming an
elongated RNA hairpin structure that is subsequently cleaved by Drosha into a small stem-loop structure of ~ 70 nt, (pre-miRNA). Pre-miRNA is exported from the nucleus into the
cytoplasm by exportin-5 and the loop is cleaved after the pre-miRNA is loaded onto Dicer, producing a double-stranded structure of miRNA and antisense miRNA*. The latter is
typically degraded, whereas the long (~22 nt) mature miRNA strand is incorporated into the miRNA-induced silencing complex (mRISC), leading to mRNA degradation or
translational repression. Mature miRNA levels are regulated via binding to ceRNAs such circular (c)RNAs, pseudogenes, and lncRNAs, which act as a sponge to prevent miRNA
binding to target mRNAs
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Regulation of miRNAs by Competing Endogenous (ce)
RNAs
Although miRNAs exert their functions via direct binding to
miRNA response elements (MREs) in target mRNAs, they are
themselves subject to regulation when they bind to MRE-
containing non-coding RNA transcripts, known as ceRNAs
(Figure 1). Pseudogenes mostly originate from gene duplica-
tion and mutation and therefore lack the ability to produce
functional protein.33 One class of pseudogenes is generated
via mRNA retrotransposition (processed pseudogenes);34 for
example, phosphatase and tensin homolog pseudogene
(PTENP)1 contains many of the 3′-UTR MREs sites found in
PTEN and is frequently lost in human cancer. PTENP1 was
found to regulate PTEN levels by sequestering its regulatory
miRNAs, including miR-19b and miR-20a.35
Long non-coding (lnc)RNAs are a class of RNA molecules
that are longer than 200 nts. Although several lncRNAs,
including X-inactive specific transcript and H19, were
described decades ago, their role in gene regulation has only
recently become known. For instance, the lncRNA homeobox
(HOX) transcript antisense RNA (HOTAIR) was shown to
interact with polycomb repressive complex 2, which is required
to suppress HOXD gene expression.36 In addition, lncRNAs
can function as decoys to sequester miRNAs and prevent their
binding to target transcripts; for example, HOTAIR was found
to regulate the expression of HER2 by acting as a miR-331-3p
sponge in gastric cancer.37
Circular (circ)RNAs are ceRNAs generated via direct
ligation of 5′ and 3′ ends of linear RNA as an intermediate
during RNA splicing.38 CircRNAs are more stable than the
linear molecule and may therefore be more efficient miRNA
sponges (Figure 1). For example, ciRS-7 and sex-determining
region Yact as sponges for miR-7 in neurons and miR-138 in
testicular tissue.39
Methods for Detecting Circulating miRNAs
Accurate quantification of circulating miRNAs in body fluids
poses a number of challenges because of their lowabundance
and small size. However, various tools have recently been
developed that overcome these obstacles, with each having
advantages and limitations (Table 1). Quantitative reverse
transcriptase real-time (qRT-)PCR is a widely used and highly
sensitive method that requires only small amounts of input
RNA.40 A major limitation of qRT-PCR is that it is oftentimes
used to quantify the levels of a defined set of miRNAs (usually
o700); as such, it cannot be used for high-throughput
profiling. Microarray platforms are an alternative method for
detecting circulating miRNA. The advantage of this method is
the ability to simultaneously detect large numbers of circulat-
ing miRNAs;41 disadvantages include a low dynamic range
and inability to detect novel (i.e., unannotated) miRNA
species. Next-generation sequencing is another technology
for detecting circulating miRNAs based on deep
sequencing.42 This method has the advantage of being able
to detect both annotated and unannotatedmiRNAs, although it
requires large amounts of starting material and generates
copious amounts of data that must be analyzed using complex
bioinformatics tools. Direct quantification of circulating miR-
NAs in bodily fluids has become possible using the Nano-
String nCounter platform,43 which is based on a novel digital
molecular barcoding technology that enables quantification of
the exact copy number of miRNA species in a biological
sample.44 However, a major limitation of this platform is that it
currently can only detect up to 800 human miRNAs per slide.
Given the strengths and shortcomings of each platform,
selecting the appropriate one will largely depend on the
available resources, type of sample, and the question being
addressed.
Sample Selection and Processing
Levels of circulating miRNAs are influenced by sample type
and RNA extraction method. Serum and plasma are the most
commonly used sample types for circulating miRNA detection.
Hemolysis can affect the abundance of circulating miR-
NAs;45,46 therefore, samples with obvious hemolysis should
be routinely excluded frommiRNA profiling studies.41We have
found serum to be a better sample choice for circulating
miRNA studies as it is less prone to hemolysis than plasma. In
addition, as miRNAs usually exist in the circulation bound to
other proteins or in apoptotic bodies or exosomes, it is
important to choose an RNA isolation method that will extract
all miRNAs present in the desired biological fraction, such as
TRIzol reagent or column-based techniques.
Table 1 Commonly used methods for quantifying circulating miRNAs
Method Advantages Disadvantages
Quantitative real-time
PCR
Highly sensitive
Requires small amounts of input RNA
Mostly used to quantify the level of a defined set of
miRNAs
Microarray Can simultaneously measure large numbers of
circulating miRNAs
Low dynamic range
Unable to detect novel unannotated miRNAs
Next-generation
sequencing
Can detect both annotated and unannotated
miRNAs
Requires large amounts of starting material
Generates copious amounts of data requiring complex
bioinformatics data analysis
NanoString nCounter Can quantify the exact copy number of miRNA
species in biological samples
Currently limited to detecting up to 800 miRNAs per
sample
Circulating microRNAs in breast cancer
R Hamam et al
3
Cell Death and Disease
Role of miRNAs in Breast Cancer
Dysregulation of miRNAs is linked to many human diseases
including myocardial infarction and cardiovascular
diseases,47,48 diabetes, obesity49–51 and cancer.52 Various
mechanisms such as DNA amplification, deletion and muta-
tions relating to miRNA loci, epigenetic silencing or inhibition
of specific miRNA processing can lead to altered miRNA
expression in human cancers53 In this section, we describe
the best-known examples of breast cancer-associated miR-
NAs, focusing on their involvement in various aspects of breast
cancer (Figure 2).
In humans, let-7 is overexpressed in differentiated epithelial
tissues and is oftentimes downregulated during tumorogen-
esis; it is known to target LIN28 mRNA and is itself a target of
negative feedback regulation by LIN28.44,52 LIN28 protein
expression is upregulated in many tumors, including breast
cancer.54 Let-7 was found to regulate breast cancer tumor-
initiating cells (T-IC) through targeting HRAS and HMGA2.55
The miR-200 family is recognized as having a tumor-
suppressor role. The family consists of five members
organized as two clusters – cluster I (miR-200b/200a/429)
and cluster II (miR-200c/141) on chromosomes 1 and 12,
respectively,56 which are suppressed during epithelial-to-
mesenchymal transition (EMT), an initiating step in metastasis
that is associated with increased breast cancer cell motility
and invasiveness.57,58 MiR-200 family members were found to
regulate BMI1 expression in breast cancer T-IC and suppress
EMT by inhibiting zinc-finger E-box binding homeobox (ZEB)1
and ZEB2.59,60 These findings were supported by another
study showing that modulation of miR-200c in breast cancer
cells affects cell migration and invasion.61 In addition,
miR-200c regulates transforming growth factor β-induced
stress fiber formation independently of the ZEB/E–cadherin
axis by targeting the actin-regulatory proteins formin homol-
ogy 2 domain containing (FHOD)1 and protein phosphatase,
Mg2+/Mn2+-dependent (PPM)1F.61 MiR-10b was first discov-
ered as an oncogenic miRNA in metastatic breast cancer cell
lines;62 miR-10b level has been linked to malignancy in
advanced-stage cancer of various types. Its expression was
also upregulated in metastatic as compared with matched
primary tumors.63 MiR-10b directly targets the HOXD10 and
Krüppel-like factor 4 genes.62,64 MiR-21 is an oncogenic
miRNA that inhibits several tumor-suppressor genes and thus
promotes cell growth and invasion and tumor metastasis.
MiR-21 is one of the most highly expressed miRNAs in
breast cancer, and its upregulation is associated with tumor
progression and poor prognosis.65,66 MiR-21 has several
targets including tropomyosin 1α and programmed cell death
(PDCD)4.66,67 MiR-21 also targets PTEN68 to promote MCF-7
breast cancer cell growth,69 as well as the tumor suppressors
acidic nuclear phosphoprotein 32 family member A and SWI/
SNF-related matrix-associated actin-dependent regulator of
chromatin subfamily A member 4.70 MiR-335, which is
oftentimes silences in breast cancer, inhibits metastasis by
Figure 2 Transcriptome–miRNA interaction networks in breast cancer. Schematic representation of the interaction of commonly altered miRNAs in breast cancer and their
identified mRNA targets regulating EMT/metastasis, stemness, growth and survival of breast cancer cells. ↑ indicated miRNA or gene is upregulated, whereas (↓) indicate miRNA
or gene is downregulated in BC tissue. Yellow filled miRNA ovals indicate miRNAs whose expression is also altered in the circulation based on current review. RHOC, Ras
homolog family member C; HOXD10, homeobox D 10; KLF4, Kruppel-like factor 4; PDCD4, programmed cell death 4; SOX4, SRY (sex-determining region Y)-box 4; TNC,
Tenascin-C; FHOD1, Formin homology 2 domain containing 1; PPM1F, protein phosphatase, Mg2+/Mn2+ Dependent 1F; ZEB1, zinc-finger E-box binding homeobox 1; ZEB2,
zinc-finger E-box binding homeobox 2; VEGFA, vascular endothelial growth factor A; LIN28B, Lin-28 homolog B; RAS, RAS viral oncogene homolog; HMGA2, high mobility group
AT-Hook 2; BMI1, BMI1 proto-oncogene, polycomb ring finger; ID4, inhibitor of DNA binding 4, HLH protein; PTEN, phosphatase and tensin homolog; BRCA1, BRCA1, DNA
repair associated; BCL2, BCL2, apoptosis regulator; SIRT1, sirtuin 1; ERBB3, Erb-B2 receptor tyrosine kinase 3
Circulating microRNAs in breast cancer
R Hamam et al
4
Cell Death and Disease
targeting the transcription factor Sry-box 4 and extracellular
matrix protein tenascin-C.71,72 The tumor-suppressor function of
miR-335 involves reducing cell viability and promoting apoptosis
by simultaneously regulating the BRCA1 activators insulin-like
growth factor 1, ER-α, and specificity protein 1 and the repressor
inhibitor of differentiation 4.73 MiR-301 acts as an oncomiR in
breast cancer via regulation of forkhead boxF2, B-cell lymphoma
2-binding component 3, PTEN and collagen 2A1.74
MiR-155 is another oncogenic miRNA that regulates multi-
ple signaling pathways related to cell growth and survival;75 it
is known to target BRCA1, a human breast cancer suscept-
ibility gene76,77 that is involved in DNA repair and cell cycle
progression. Other genes associated with breast cancer
progression such as suppressor of cytokine signaling 1 and
forkhead box O3a are negatively regulated by miR-155.78
MiR-34a is oftentimes downregulated in breast cancer,
which promotes breast cancer growth and survival through
upregulation of SIRT1 and BCL2 proteins.79,80 miR-205 is
frequently downregulated in metastatic breast cancer. Loss of
miR-205 promoted breast cancer cell growth and invasion
through upregulation of Erb-B2 receptor tyrosine kinase 3,
vascular endothelial growth factor A, ZEB1 and ZEB2
proteins.81–83
Circulating miRNAs as Disease Biomarkers
Cell-free circulating miRNAs usually exist bound to ribonu-
cleoprotein complexes or high-density lipoprotein or they are
released from cells in lipid vesicles, microvesicles, exosomes
or apoptotic bodies (Figure 3).84–87 Lipid vesicles and
exosomes have critical roles in cell–cell communication.87,88
Thus, circulatingmiRNAsmay reflect homeostatic response of
the organism, as well as signs of disease progression.
Circulating miRNAs have been detected in the peripheral
blood circulation and other body fluids.89,90,91 Owing to their
stability and resistance to endogenous RNase activity, these
miRNAs have been proposed as diagnostic and prognostic
biomarkers for diseases, such as cancer, diabetes mellitus
and neurological disorders.92–95 Table 2 summarizes the
frequently upregulated circulating miRNAs in human cancers.
Elevated levels of miR-21 and -210 in the serum have been
reported in patients with diffuse large B-cell lymphoma; the
former is associated with relapse-free survival.96 Increased
serum levels of various miRNAs have been linked to different
human cancers – for instance, miR-141 in prostate cancer;91
miR-25 and miR-223 in lung cancer;89 miR-21, miR-92,
miR-93, miR-126 and miR-29a in ovarian cancer;97 miR-92
and miR-17-3p in colorectal cancer;98 miR-92a in acute
leukemia;99 miR-210, miR-21, miR-155 and miR-196a in
pancreatic cancer;100,101 miR-184 in squamous cell carci-
noma of the tongue;102 and miR-500 in hepatocellular
carcinoma.103
A large number of studies have reported the usefulness of
miRNAs as diagnostic, prognostic, or predictive biomarkers for
breast cancer. Table 3 list characteristics of the studies
including number of patients included, verification of miRNAs
identified using alternative methods and confirmation of the
findings in an independent cohort of patients. As seen in
Table 3, studies varied in their quality based on these quality
criteria. In the following sections, we will discuss how
circulating miRNAs have been used in the context of breast
cancer biology as diagnostic, prognostic and predictive
biomarkers.
Figure 3 Sources and forms of circulating miRNAs. MiRNAs can be released via an active process in the form of exosomes (o100 nM) through the course of exocytosis (a
process that involves fusion of the multivesicular body (MVBs) with the plasma membrane) or as microvesicles (100–1000 nM, through outward budding from the plasma
membrane). Alternatively, miRNAs can be released as a result of necrosis or apoptosis (programmed cell death). Cell-free circulating miRNAs usually exist bound to
ribonucleoprotein complexes (such as Argonaute-2), or high-density lipoprotein (HDL). Circulating miRNAs are also found within lipid microvesicles and exosomes
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Circulating miRNAs as diagnostic biomarkers. Heneghan
and colleagues104 assessed the diagnosis potential of a
panel of seven cancer-associated miRNAs in the circulation
of patients with various cancer types. The authors found that
let-7a and miR-10b and -155 levels were upregulated in the
majority of cancer patients, whereas circulating miR-195 level
distinguished those with breast cancer from other cancer
types and from normal control with a sensitivity of 88% and a
specificity of 91%. The sensitivity was further increased to
94% when using a combination of circulating levels of
miR-195, let-7a and miR-155. Another study explored the
diagnostic potential of a panel of circulating miRNAs targeting
PTEN tumor suppressor using qRT-PCR in a cohort of breast
cancer patients. The preoperative levels of circulating
miR-20a and -21 were higher in patients with breast cancer
and benign disease compared with healthy controls, whereas
levels of circulating miR-214 were able to discriminate
between malignant and benign tumors and healthy
subjects.105 Cuk et al.106 explored the diagnostic potential
of a seven circulating miRNA panel (miR-127-3p, miR-148b,
miR-376a, miR-376c, miR-409-3p, miR-652 and miR-801) in
two cohorts of breast cancer patients. The authors observed
elevated levels of these miRNAs in the circulation from breast
cancer patients. MiR-127-3p, miR-148b, miR-409-3p,
miR-652 and miR-801 were detected in breast cancer stages
I and II, suggesting that they can be used for early diagnosis.
In another study, miRNA expression profiling using plasma
samples from breast cancer patients and healthy controls
revealed 43 miRNAs that were differentially expressed
between the two groups, with patients exhibiting higher
miR-148b, miR-133a and miR-409-3p levels. miR-148b and
miR-133a were also detected in breast cancer cell lines,
suggesting their tumor origin.107 A recent study performed
global profiling of circulation miRNA in patients with ER-
positive early-stage breast cancer and age-matched healthy
controls. The authors identified a panel of nine miRNAs
(miR-15a, miR-18a, miR-107, miR-133a, miR-139-5p,
miR-143, miR-145, miR-365 and miR-425) that can discrimi-
nate between patients with breast cancer and healthy
controls. This panel was subsequently validated in a second
cohort of patients with early-stage breast cancer.108 A study
using the Taqman low-density array platform comparing
patients with early breast cancer and healthy controls found
that circulating miR-484 level was higher in patients with
breast cancer, which was validated in a second cohort of
patients with early-stage breast cancer.109 Although several
of the aforementioned studies included a modest number of
patients, Shimomura et al.110 conducted microarray expres-
sion profiling using sera from a cohort of 1280 patients with
breast cancer, 2836 controls, 451 from patients with other
cancer types and 63 from patients with non-breast benign
diseases. The authors divided the samples into training and
validation cohorts and identified a panel of five miRNAs
(miR-1246, miR-1307-3p, miR-4634, miR-6861-5p and miR-
-6875-5p) that discriminated between patients with breast
cancer and those with other cancer types and controls. In
another study, serum miR-155, miR-19a, miR-181b and
miR-24 levels were elevated in patients with early-stage
breast cancer relative to healthy subjects at the time of
diagnosis, and were higher in high-risk as compared with low-
risk patients. Interestingly, miR-155, miR-181b and miR-24
expression declined after surgical resection whereas that of
miR-19a decreased post-therapy.111
However, one limitation of the above-mentioned studies is
that the origin of detected circulating miRNAs has not been
verified and in particular, the contribution of breast cancer
tissue to the identified circulating miRNAs is not known. A
number of studies examined the association between the
expression of selected miRNA panels in breast cancer tissues
and their correlation with circulating miRNAs. For instance,
global profiling of miRNA expression in breast cancer tumor
tissue, normal tissue and serum samples obtained from
patients and from healthy controls revealed significant dereg-
ulation in the expression level of several miRNAs in both tissue
and circulation. In particular, miR-1, miR-92a, miR-133a and
miR-133b were the most prominently upregulated diagnostic
markers in breast cancer sera, which was subsequently
validated in an independent cohort of patients with breast
cancer.112 Matamala et al.113 performed global miRNA
expression profiling using paraffin-embedded tissue from
patientswith breast cancer and samples from healthy controls;
in two independent cohorts of breast cancer versus control,
they identified and validated four miRNAs (miR-505-5p,
miR-125b-5p, miR-21-5p and miR-96-5p) that were signifi-
cantly overexpressed in tissue and circulation of pretreated
patients with breast cancer. In another study, Li et al.114
assessed the expression of Let-7c in breast cancer tissue
compared with adjacent para-carcinoma control tissue. The
authors reported significant downregulation in Let-7c in breast
cancer. The tissue findings were subsequently verified using
sera of patients with breast cancer that revealed lower levels
of let-7c compared with serum levels in healthy controls.
Table 2 List of selected circulating miRNAs in various human cancers
MiRNA Cancer type Regulation Reference
Mir-21 and -210 B-cell lymphoma Up 96
MiR-141 Prostate cancer Up 91
MiR-25 and -223 Lung cancer Up 89
MiR-21, -92, -93, -126, and -29a Ovarian cancer Up 97
MiR-17-3p and -92 Colorectal cancer Up 98
MiR-92a Acute Leukemia Up 99
MiR-210, -21, -155, and -196a Pancreatic cancer Up 100,101
MiR-184 Squamous cell carcinoma Up 102
MiR-500 Hepatocellular carcinoma Up 103
Circulating microRNAs in breast cancer
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Wang et al.115 assessed the diagnostic potential of circulating
miR-182 in breast cancer patients. High serum levels of
circulating miR-182 measured by qRT-PCR were detected in
breast cancer patients as compared with healthy controls and
miR-182 was also overexpressed in breast cancer tissue,
suggesting that it is potential use as a diagnostic biomarker.
Although in the above-mentioned studies a good concordance
was observed in miRNAs profile detected in breast cancer
tumor tissue and in the circulation, some studies suggested a
non-tumor origin of circulating miRNAs. Waters and
colleagues116 used a murine model of breast cancer to
assess changes in circulating miRNA expression during tumor
progression. Of particular interest, circulating miR-138 was
upregulated in the murine xenograft model of breast cancer,
whose upregulated expression was subsequently validated in
the sera from patients with breast cancer. Interestingly, the
authors did not observe any change in miR-138 levels in
breast cancer tissues itself.
miRNA expression profiling of breast cancer tissue revealed
that several miRNAs exhibited expression pattern associated
with breast cancer molecular subtype, ER status or other
pathological features.117,118 Therefore, a number of studies
assessed potential utilization of circulating miRNAs in breast
cancer disease stratification. In one study, Zhu et al.119
assessed the expression of circulating miR-16, miR-145 and
miR-155 in a cohort of breast cancer patients compared with
those in healthy controls. Although there was no difference in
the expression of this miRNA panel in breast cancer, miR-155
was found to be highly expressed in progesterone (PR)-
positive patients. Wang and colleagues120 correlated the
expression of selected panel of miRNAs in breast cancer
tissues and matched serum samples. The authors observed
miR-21, miR-106a and miR-155 levels to be elevated,
whereas those of miR-126, miR-199a and miR-335 to be
reduced in tumor specimens relative to normal tissue.
Interestingly, circulating levels of miR-21, miR-126, miR-155,
miR-199a and miR-335 were associated with histological
tumor grade and sex hormone receptor expression. Recently
our group isolated and performed an enrichment step before
global expression profiling of circuiting miRNAs in breast
cancer patients compared with normal controls. We identified
a novel panel of nine circulating miRNAs (miR-4270, miR-
-1225-5p, miR-188-5p, miR-1202, miR-4281, miR-1207-5p,
miR-642b-3p, miR-1290 and miR-3141) that was upregulated
in patients with breast cancer, and whose expression was
correlated with cancer stage and molecular subtype.41
Circulating miRNAs as prognostic biomarkers. Circulat-
ing miRNAs can also serve as prognostic biomarkers in
breast cancer patients (Table 3). A prognostic biomarker
should indicate patient’s outcome, for example, disease
recurrence or disease progression, independent of treatment
received. In one study, serum levels of melanoma-associated
antigen-A1, -A2, -A3 and -A12 and CCCTC-binding factor-
like mRNA, as well as that of let-7b were higher in patients
with invasive breast cancer compared with those with non-
invasive tumors, benign breast disease or healthy controls. In
this study, miR-202 overexpression was positively correlated
with reduced overall survival.121 In another study, Mangolini
and colleagues122 used droplet digital PCR to assess the
prognostic value of a five circulating miRNA (miR-10b-5p,
miR-145-5p, miR-148b-3p, miR-425-5p and miR-652-3p)
panel chosen based on prior circulating miRNA expression
profiling study. The authors reported that serum levels of
miR-148b-3p and miR-652-3p were lower, whereas higher
expression of miR-10b-5p correlated with poor prognosis in
two cohorts of breast cancer patients. A recent study
investigated the prognostic value of circulating miRNAs in
patients with primary triple-negative breast cancer (TNBC).
The authors conducted genome-wide miRNA expression
profiling using serum from TNBC patients, which revealed a
four-miRNA signature (miR-18b, miR-103, miR-107 and
miR-652) that could predict tumor relapse and overall
survival.123
Several studies has also investigated the potential correla-
tion betweenmiRNA profile expression in the circulation and in
breast cancer metastastic tissue and their possible use to
diagnose generalized metastatic disease. Based on the
observation that miR-10b and miR-373 are overexpressed in
breast cancer lymph node metastases, circulating levels of
miR-10b and miR-373 were assessed in the sera for their
potential utilization as biomarker for detecting breast cancer
lymph node metastases. The authors reported higher levels of
miR-10b and miR-373 in plasma from preoperative breast
cancer patients with lymph node metastasis compared with
patients without metastasis and normal controls.124 In another
study, serum levels of four breast cancer-associated miRNAs
(miR-10b, miR-34a, mi-R141 and miR-155) were measured in
patients with primary or metastatic breast cancer, and healthy
controls using qRT-PCR. Increased expression of circulating
miR-34a was correlated with tumor stage, whereas upregula-
tion of miR-10b, miR-34a and miR-155 was associated with
the presence of metastases.125 Shaker et al.126 assessed the
expression of four miRNAs in the sera of female patients with
breast cancer and healthy controls and reported increased
levels of miR-29b-2, miR-155, miR-197 and miR-205 in
patients with breast cancer and the levels of these miRNAs
correlated with tumor grade (T3 versus T2) and the presence
of lymph node metastases (N3 versus N2), whereas expres-
sion of only miR-155 and miR-205 correlated with the
presence of distant metastases. miRNA expression profiling
performed on breast cancer tissue, serum samples from
patients with early-stage breast cancer and healthy controls
revealed that the level of miR-92a was reduced whereas that
of miR-21 was increased in the tissue and serum of patients
with early-stage breast cancer relative to controls. Further-
more, serum miR-92a and -21 levels were correlated with
tumor size and the presence of lymph node metastases.127 In
addition, miRNA profiling of recurrent, non-recurrent and
healthy controls identified 22 miRNAs, which were subse-
quently validated in an independent cohort of non-recurrent
and recurrent breast cancer patients’ sera. Upregulation of
miR-21-5p, miR-375, miR-205-5p and miR-194-5p and down-
regulation of miR-382-5p, miR-376c-3p and miR-411-5p have
been linked to breast cancer recurrence.128 Another study has
reported an association between the expression of cell-free
exosomal miRNAs circulating in serum and the molecular
subtypes of breast cancer. The authors measured the
expression levels of six circulating miRNAs (miR-10b, miR-17,
miR-34a, miR-93, miR-155 and miR-373) in the sera of
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patients with primary (M0), and metastatic (M1) breast cancer
and those of healthy controls. The authors observed sig-
nificant differences in the expression levels of circulating
miR-34a, miR-93 and miR-373 between the patients with M0
breast cancer and healthy controls, whereas the levels of
miR-17 and miR-155 were significantly higher in the M0
compared with those in the M1 group. Elevated levels of
miR-373 were associated with HER2-negative status of the
primary tumor, whereas levels of miR-17 and miR-34a
correlated with PR or ER status.129
Circulating miRNAs as predictive biomarkers. Only few
studies have investigated the value of circulating miRNAs in
breast cancer patients as predictive biomarkers for treatment
response. In one study, expression of four breast cancer-
associated miRNAs (miR-10b, miR-34a, miR-125b and miR-
-155) was profiled in the sera from breast cancer patients with
invasive ductal carcinoma and preoperative neoadjuvant
chemotherapy before treatment and normal controls. Among
the studied miRNAs, only miR-125b exhibited higher expres-
sion level in non-responder breast cancer patients suggesting
possible correlation between miR-125b expression in the
circulation and breast cancer chemotherapeutic
resistance.130 In an independent study, Wu and
colleagues42 performed deep sequencing of circulating
miRNAs on pre-treatment sera obtained from a cohort of
stages II–III locally advanced breast cancer patients who
received neoadjuvant chemotherapy followed by surgical
resection of the tumor. The authors observed that reduced
level of miR-375 and elevated levels of miR-122 were able to
discriminate between relapsed and non-relapsed patients,
whereas elevated levels of miR-375, miR-184, miR-1299 and
miR-196a and reduced levels of miR-381, miR-410 and
miR-1246 were observed in good responder to neoadjuvant
chemotherapy. The authors subsequently validated miR-122
in a second cohort of stages II–III BC patients and
demonstrated significant association between elevated
expression of circulating miR-122 and patient relapse,
suggesting potential utilization of miR-122 and miR-375 in
predicting response to chemotherapy in BC patients and
relapse. Sun and colleagues131 used qRT-PCR to assess the
expression of miR-155 in the sera from breast cancer
patients compared with healthy individuals and reported
elevated circulating levels of miR-155 in breast cancer.
Interestingly, the levels of miR-155 in the serum decreased
after surgery and four cycles of chemotherapy suggesting
potential utilization of miR-155 as an indicator for treatment
response.
Limitations of Using miRNAs as Breast Cancer
Biomarkers
The establishment of an accurate and reliable panel of
circulating miRNAs for breast cancer diagnosis, prognosis
and prediction of treatment response, is challenging at nearly
every step from sample collection and processing to data
analysis.132 A major limitation to using circulating miRNAs as
biomarkers is their low abundance, which hampers their
detection using standard miRNA profiling techniques such as
microarrays. Modified approaches have been proposed as a
solution: for example, we recently developed a new strategy
that relies on miRNA isolation and enrichment before global
expression profiling.41 Another important issue is sample
selection and processing. The majority of studies use serum,
or plasma. We found that serum is a better choice to avoid
drawbacks of excluding a large number of samples because of
the presence of hemolysis. Notably, circulating miRNA levels
are higher in serum than in plasma, implying potential
interference by platelet and white blood cell during sample
preparation.133 It is therefore important to use the same type of
material (for patients and controls), avoid samples showing
signs of hemolysis and use a standardized protocol of sample
collect and processing. Patient selection and classification is a
critical issue for clinical studies. A number of studies have
reported fluctuations in circulating miRNA levels in response
to chemotherapy.134–136 To eliminate this problem, patients’
treatment regimen must be considered, or else blood samples
must be collected before chemotherapy. Another important
factor is the choice of platform for measurement of miRNA
level. It is clear that the majority of studies listed in Table 3 are
qRT-PCR-based. Although this method is more sensitive and
less costly than others, a major limitation is the inability to
detect novel miRNAs; indeed, most studies used a pre-
existing circulating miRNA panel or screened for miRNAs that
have been detected in tissue. Finally, there is a lack of reliable
housekeeping circulating miRNAs for normalization of expres-
sion levels, which can change with physiological and
pathological status. As such, other approaches for normal-
ization have been used, such as using equal amounts of
starting material (serum or plasma)41 or a synthetic spike-in
control, which was found to be more reliable than endogenous
miRNAs for data normalization.137
As observed in the above appraisal of the published studies,
there is a minimal overlap in the identified miRNA panels
among different studies, which reflects a complex biology of
miRNA expression in BC patient’s circulation. Breast cancer is
a heterogeneous group of diseases with diverse biological
behaviors that correspond to heterogeneous cancer tissue
structure and gene expression profile. The discrepancy in the
identified circulating miRNA signatures reported by different
groups, may be caused by the heterogeneity of the disease
and its clinical presentation. The variability may also be
caused by the significant contribution of many tissues to the
circulating miRNAs. Circulating exosomes and microvesicles
are carrier of miRNAs in the circulation and their content and
biological functions are dependent on their cell of origin;138 a
potential solution to obtain a breast cancer-specific profile is to
enrich tumor-specific miRNAs through isolation of circulating
microvesicles usingmarkers specific to the tissue of origin. For
instance, epithelial cell adhesion molecule (EpCAM)-positive
microvesicles were isolated from ovarian cancer for miRNA
profiling.139
Conclusions
Circulating miRNAs hold a great promise as diagnostic,
prognostic or predictive biomarkers in the clinical manage-
ment of patients with breast cancer. In our review of the current
state of knowledge in the field, we observed little consistency
with respect to the circulating miRNA panels identified by
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different research groups, hence currently we do not have
clinically useful panel of circulating miRNA to be used in the
oncology practice. This is in part because of variations in
patient selection and techniques used to isolate and measure
circulating miRNAs, their low abundance, the effects of
therapy, and concurrent diseases, inadequate sample sizes,
inadequate statistical analysis, and insufficient numbers of
validation studies testing their clinical utilization. A number of
issues related to sample collection, method of measurements
and normalization are still in need for standardization and
streamlining, whereas a number of approaches are currently
under development to enhance detection sensitivity and
specificity and improve the clinical applications of miRNAs.
Multi-center global profiling studiesmay provide useful data for
identifying diagnostic, prognostic, or predictive circulating
miRNA panels. Although these issuesmay hamper the clinical
use of miRNA profiling in clinical practice, their use as
research tools to understand and possibly target cancer cells
and cancer stem cells are currently rich areas for clinical
investigation.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. The authors thank the Deanship of Scientific Research at
King Saud University (research group no. RG-1438-032) for funding this work. The
funder had no role in the preparation of the manuscript or decision to publish.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional
claims in published maps and institutional affiliations.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics2015 CA Cancer J Clin 2015; 65: 5–29.
2. Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD. The descriptive
epidemiology of female breast cancer: an international comparison of screening, incidence,
survival and mortality. Cancer Epidemiol 2012; 36: 237–248.
3. International Agency for research on Cancer. GLOBOCAN Cancer Fact Sheets: Breast
cancer http://globocan.iarc.fr/old/FactSheets/cancers/breast-new.asp Accessed 10 Octo-
ber 2016.
4. Jorgensen KJ, Kalager M, Barratt A, Baines C, Zahl PH, Brodersen J et al. Overview of
guidelines on breast screening: why recommendations differ and what to do about it. Breast
2016; 31: 261–269.
5. Charles L, Loprinzi FRA, Martee L, Hensley JTR. ASCO SEP. 3rd edn. American Society
of Clinical Oncology, Alexandria, VA, USA, 2013.
6. Ellsworth RE, Blackburn HL, Shriver CD, Soon-Shiong P, Ellsworth DL. Molecular
heterogeneity in breast cancer: state of the science and implications for patient care. Semin
Cell Dev Biol 2016; 64: 65–72.
7. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al. A multigene assay to predict
recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:
2817–2826.
8. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on
protein output. Nature 2008; 455: 64–71.
9. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J et al. Microarray
analysis shows that some microRNAs downregulate large numbers of target mRNAs.
Nature 2005; 433: 769–773.
10. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread
changes in protein synthesis induced by microRNAs. Nature 2008; 455: 58–63.
11. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007; 23: 175–205.
12. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved
targets of microRNAs. Genome Res 2009; 19: 92–105.
13. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009;
136: 642–655.
14. Davis BN, Hata A. Regulation of microRNA biogenesis: a miRiad of mechanisms. Cell
Commun Signal 2009; 7: 18.
15. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional
regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9: 102–114.
16. Forman JJ, Legesse-Miller A, Coller HA. A search for conserved sequences in coding
regions reveals that the let-7 microRNA targets Dicer within its coding sequence. Proc Natl
Acad Sci USA 2008; 105: 14879–14884.
17. Hausser J, Landthaler M, Jaskiewicz L, Gaidatzis D, Zavolan M. Relative contribution of
sequence and structure features to the mRNA binding of Argonaute/EIF2C-miRNA
complexes and the degradation of miRNA targets. Genome Res 2009; 19: 2009–2020.
18. Hendrickson DG, Hogan DJ, McCullough HL, Myers JW, Herschlag D, Ferrell JE et al.
Concordant regulation of translation and mRNA abundance for hundreds of targets of a
human microRNA. PLoS Biol 2009; 7: e1000238.
19. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can
up-regulate translation. Science 2007; 318: 1931–1934.
20. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA
biogenesis pathways and their regulation. Nat Cell Biol 2009; 11: 228–234.
21. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J et al. The nuclear RNase III Drosha initiates
microRNA processing. Nature 2003; 425: 415–419.
22. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH et al. MicroRNA genes are transcribed by
RNA polymerase II. EMBO J 2004; 23: 4051–4060.
23. Zeng Y, Yi R, Cullen BR. Recognition and cleavage of primary microRNA precursors by the
nuclear processing enzyme Drosha. EMBO J 2005; 24: 138–148.
24. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA
precursors. Science 2004; 303: 95–98.
25. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-
microRNAs and short hairpin RNAs. Genes Dev 2003; 17: 3011–3016.
26. Ding XC, Weiler J, Grosshans H. Regulating the regulators: mechanisms controlling the
maturation of microRNAs. Trends Biotechnol 2009; 27: 27–36.
27. Bosse GD, Simard MJ. A new twist in the microRNA pathway: not Dicer but Argonaute is
required for a microRNA production. Cell Res 2010; 20: 735–737.
28. Hutvagner G, Simard MJ. Argonaute proteins: key players in RNA silencing. Nat Rev Mol
Cell Biol 2008; 9: 22–32.
29. Giraldez AJ, Mishima Y, Rihel J, Grocock RJ, Van Dongen S, Inoue K et al. Zebrafish
MiR-430 promotes deadenylation and clearance of maternal mRNAs. Science 2006; 312:
75–79.
30. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E et al. Inhibition of
translational initiation by Let-7 MicroRNA in human cells. Science 2005; 309: 1573–1576.
31. Zeng Y, Cullen BR. Sequence requirements for micro RNA processing and function in
human cells. RNA 2003; 9: 112–123.
32. Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev 2003;
17: 438–442.
33. Li WH, Gojobori T, Nei M. Pseudogenes as a paradigm of neutral evolution. Nature 1981;
292: 237–239.
34. Vanin EF. Processed pseudogenes: characteristics and evolution. Annu Rev Genet 1985;
19: 253–272.
35. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-
independent function of gene and pseudogene mRNAs regulates tumour biology. Nature
2010; 465: 1033–1038.
36. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA et al. Functional
demarcation of active and silent chromatin domains in human HOX loci by
noncoding RNAs. Cell 2007; 129: 1311–1323.
37. Liu XH, Sun M, Nie FQ, Ge YB, Zhang EB, Yin DD et al. Lnc RNA HOTAIR functions as a
competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in
gastric cancer. Mol Cancer 2014; 13: 92.
38. Lasda E, Parker R. Circular RNAs: diversity of form and function. RNA 2014; 20:
1829–1842.
39. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK et al. Natural
RNA circles function as efficient microRNA sponges. Nature 2013; 495: 384–388.
40. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in
plasma and serum using quantitative reverse transcription-PCR (qRT-PCR).Methods 2010;
50: 298–301.
41. Hamam R, Ali AM, Alsaleh KA, Kassem M, Alfayez M, Aldahmash A et al. microRNA
expression profiling on individual breast cancer patients identifies novel panel of circulating
microRNA for early detection. Sci Rep 2016; 6: 25997.
42. Wu X, Somlo G, Yu Y, Palomares MR, Li AX, Zhou W et al. De novo sequencing of
circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced
breast cancer. J Transl Med 2012; 10: 42.
43. Oikonomopoulos A, Polytarchou C, Joshi S, Hommes DW, Iliopoulos D. Identification of
circulating microRNA signatures in Crohn's disease using the Nanostring nCounter
technology. Inflamm Bowel Dis 2016; 22: 2063–2069.
44. Alajez NM, Shi W, Wong D, Lenarduzzi M, Waldron J, Weinreb I et al. Lin28b promotes
head and neck cancer progression via modulation of the insulin-like growth factor survival
pathway. Oncotarget 2012; 3: 1641–1652.
45. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N et al.
Haemolysis during sample preparation alters microRNA content of plasma. PLoS ONE
2011; 6: e24145.
46. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating
microRNA: preanalytical and analytical challenges. Clin Chem 2011; 57: 833–840.
Circulating microRNAs in breast cancer
R Hamam et al
10
Cell Death and Disease
47. Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S et al. Functional
screening identifies miRNAs inducing cardiac regeneration. Nature 2012; 492: 376–381.
48. Quiat D, Olson EN. MicroRNAs in cardiovascular disease: from pathogenesis to prevention
and treatment. J Clin Invest 2013; 123: 11–18.
49. Cao L, Lin EJ, Cahill MC, Wang C, Liu X, During MJ. Molecular therapy of obesity and
diabetes by a physiological autoregulatory approach. Nat Med 2009; 15: 447–454.
50. Hilton C, Neville MJ, Karpe F. MicroRNAs in adipose tissue: their role in adipogenesis and
obesity. Int J Obes (Lond) 2012; 37: 325–332.
51. Dehwah MA, Xu A, Huang Q. MicroRNAs and type 2 diabetes/obesity. J Genet Genomics
2012; 39: 11–18.
52. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev
Genet 2009; 10: 704–714.
53. Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J et al. MiR-218 suppresses
nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-
ROBO1 pathway. Cancer Res 2011; 71: 2381–2391.
54. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S et al. Lin28
promotes transformation and is associated with advanced human malignancies. Nat Genet
2009; 41: 843–848.
55. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. let-7 regulates self renewal and
tumorigenicity of breast cancer cells. Cell 2007; 131: 1109–1123.
56. Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A et al. Clustering and
conservation patterns of human microRNAs. Nucleic Acids Res 2005; 33: 2697–2706.
57. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H et al. NF-kappaB
is essential for epithelial-mesenchymal transition and metastasis in a model of breast
cancer progression. J Clin Invest 2004; 114: 569–581.
58. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C et al. Twist, a master
regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117:
927–939.
59. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D et al. Downregulation of
miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138:
592–603.
60. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal
transition and cancer cell migration by direct targeting of E-cadherin transcriptional
repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910–14914.
61. Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S et al.
MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-
regulatory proteins FHOD1 and PPM1F. Mol Cell Biol 2012; 32: 633–651.
62. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by
microRNA-10b in breast cancer. Nature 2007; 449: 682–688.
63. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP et al. MicroRNA expression
profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009; 219:
214–221.
64. Rowland BD, Peeper DS. KLF4, p21 and context-dependent opposing forces in cancer. Nat
Rev Cancer 2006; 6: 11–23.
65. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed
cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast
cancer cells. J Biol Chem 2008; 283: 1026–1033.
66. Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin
1 (TPM1). J Biol Chem 2007; 282: 14328–14336.
67. Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R et al. High miR-21 expression in
breast cancer associated with poor disease-free survival in early stage disease and high
TGF-beta1. Breast Cancer Res Treat 2009; 117: 131–140.
68. Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM. Estradiol
downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7
breast cancer cells. Nucleic Acids Res 2009; 37: 2584–2595.
69. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007;
26: 2799–2803.
70. Schramedei K, Morbt N, Pfeifer G, Lauter J, Rosolowski M, Tomm JM et al. MicroRNA-21
targets tumor suppressor genes ANP32A and SMARCA4. Oncogene 2011; 30:
2975–2985.
71. Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimner A et al.MicroRNA-335 inhibits tumor
reinitiation and is silenced through genetic and epigenetic mechanisms in human
breast cancer. Genes Dev 2011; 25: 226–231.
72. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD et al. Endogenous
human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147–152.
73. Heyn H, Engelmann M, Schreek S, Ahrens P, Lehmann U, Kreipe H et al. MicroRNA
miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int J
Cancer 2011; 129: 2797–2806.
74. Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M et al. MicroRNA-301 mediates
proliferation and invasion in human breast cancer. Cancer Res 2011; 71: 2926–2937.
75. Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: a typical multifunctional
microRNA. Biochim Biophys Acta 2009; 1792: 497–505.
76. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility
gene products and participants in DNA double-strand break repair. Carcinogenesis 2010;
31: 961–967.
77. Szabo CI, King MC. Inherited breast and ovarian cancer. HumMol Genet 1995; 4 Spec No:
1811–1817.
78. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H et al. MicroRNA-155 functions as an
OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer
Res 2010; 70: 3119–3127.
79. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis.
Proc Natl Acad Sci USA 2008; 105: 13421–13426.
80. Li L, Yuan L, Luo J, Gao J, Guo J, Xie X. MiR-34a inhibits proliferation and migration of
breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med 2013; 13:
109–117.
81. Wu H, Zhu S, Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer.
Cell Res 2009; 19: 439–448.
82. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T et al. microRNA-205 regulates
HER3 in human breast cancer. Cancer Res 2009; 69: 2195–2200.
83. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al. The miR-200 family
and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat
Cell Biol 2008; 10: 593–601.
84. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are
transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell
Biol 2011; 13: 423–433.
85. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated
transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange
between cells. Nat Cell Biol 2007; 9: 654–659.
86. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES,
Lindenberg JL et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci
USA 2010; 107: 6328–6333.
87. Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and
function. Trends Biochem Sci 2012; 37: 460–465.
88. Al-toub M, Vishnubalaji R, Hamam R, Kassem M, Aldahmash A, Alajez NM. CDH1 and IL1-
beta expression dictates FAK and MAPKK-dependent cross-talk between cancer cells and
human mesenchymal stem cells. Stem Cell Res Ther 2015; 6: 135.
89. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K et al. Characterization of microRNAs in serum: a
novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18:
997–1006.
90. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N et al. Serum microRNAs
are promising novel biomarkers. PLoS ONE 2008; 3: e3148.
91. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al.
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad
Sci USA 2008; 105: 10513–10518.
92. Chin LJ, Slack FJ. A truth serum for cancer–microRNAs have major potential as cancer
biomarkers. Cell Res 2008; 18: 983–984.
93. Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat
Rev Endocrinol 2013; 9: 513–521.
94. Gandhi R, Healy B, Gholipour T, Egorova S, Musallam A, Hussain MS et al. Circulating
microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol 2013; 73:
729–740.
95. Khoo SK, Petillo D, Kang UJ, Resau JH, Berryhill B, Linder J et al. Plasma-based
circulating MicroRNA biomarkers for Parkinson's disease. J Parkinson's Dis 2012; 2:
321–331.
96. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K et al. Detection of
elevated levels of tumour-associated microRNAs in serum of patients with diffuse large
B-cell lymphoma. Br J Haematol 2008; 141: 672–675.
97. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of
differentially expressed microRNAs from the serum of ovarian cancer patients using a novel
real-time PCR platform. Gynecol Oncol 2009; 112: 55–59.
98. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J et al. Differential expression of
microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal
cancer screening. Gut 2009; 58: 1375–1381.
99. Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K et al. Down-
regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS
ONE 2009; 4: e5532.
100. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT et al. Circulating
miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 2010; 3: 109–113.
101. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL et al. MicroRNAs in plasma of
pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease.
Cancer Prevent Res 2009; 2: 807–813.
102. Wong TS, Ho WK, Chan JY, Ng RW, Wei WI. Mature miR-184 and squamous cell
carcinoma of the tongue. Sci World J 2009; 9: 130–132.
103. Yamamoto Y, Kosaka N, Tanaka M, Koizumi F, Kanai Y, Mizutani T et al. MicroRNA-500
as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009; 14:
529–538.
104. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic miRNA-195 differentiates
breast cancer from other malignancies and is a potential biomarker for detecting
noninvasive and early stage disease. Oncologist 2010; 15: 673–682.
105. Schwarzenbach H, Milde-Langosch K, Steinbach B, Muller V, Pantel K. Diagnostic potential
of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat
2012; 134: 933–941.
106. Cuk K, Zucknick M, Madhavan D, Schott S, Golatta M, Heil J et al. Plasma microRNA panel
for minimally invasive detection of breast cancer. PLoS ONE 2013; 8: e76729.
Circulating microRNAs in breast cancer
R Hamam et al
11
Cell Death and Disease
107. Shen J, Hu Q, Schrauder M, Yan L, Wang D, Medico L et al. Circulating miR-148b and
miR-133a as biomarkers for breast cancer detection. Oncotarget 2014; 5: 5284–5294.
108. Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS et al. Novel circulating
microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage
breast cancer: a case control study. Mol Oncol 2014; 8: 874–883.
109. Zearo S, Kim E, Zhu Y, Zhao JT, Sidhu SB, Robinson BG et al. MicroRNA-484 is more
highly expressed in serum of early breast cancer patients compared to healthy volunteers.
BMC Cancer 2014; 14: 200.
110. Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J et al. Novel
combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci
2016; 107: 326–334.
111. Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, Burda P et al.Oncogenic microRNAs:
miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer
in serum. BMC Cancer 2014; 14: 448.
112. Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA et al. Identification of
circulating microRNA signatures for breast cancer detection. Clin Cancer Res 2013; 19:
4477–4487.
113. Matamala N, Vargas MT, Gonzalez-Campora R, Minambres R, Arias JI, Menendez P et al.
Tumor microRNA expression profiling identifies circulating microRNAs for early breast
cancer detection. Clin Chem 2015; 61: 1098–1106.
114. Li XX, Gao SY, Wang PY, Zhou X, Li YJ, Yu Y et al. Reduced expression levels of let-7c in
human breast cancer patients. Oncol Lett 2015; 9: 1207–1212.
115. Wang PY, Gong HT, Li BF, Lv CL, Wang HT, Zhou HH et al. Higher expression of
circulating miR-182 as a novel biomarker for breast cancer. Oncol Lett 2013; 6:
1681–1686.
116. Waters PS, Dwyer RM, Brougham C, Glynn CL, Wall D, Hyland P et al. Impact of tumour
epithelial subtype on circulating microRNAs in breast cancer patients. PLoS ONE 2014; 9:
e90605.
117. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ et al. MicroRNA
expression profiling of human breast cancer identifies new markers of tumor subtype.
Genome Biol 2007; 8: R214.
118. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al. MicroRNA gene
expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065–7070.
119. Zhu W, Qin W, Atasoy U, Sauter ER. Circulating microRNAs in breast cancer and healthy
subjects. BMC Res Notes 2009; 2: 89.
120. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant
expression in tissues and sera from patients with breast tumor. Gynecol Oncol 2010; 119:
586–593.
121. Joosse SA, Muller V, Steinbach B, Pantel K, Schwarzenbach H. Circulating cell-free
cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with
breast cancer and benign breast diseases. Br J Cancer 2014; 111: 909–917.
122. Mangolini A, Ferracin M, Zanzi MV, Saccenti E, Ebnaof SO, Poma VV et al. Diagnostic and
prognostic microRNAs in the serum of breast cancer patients measured by droplet
digital PCR. Biomark Res 2015; 3: 12.
123. Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Borresen-Dale AL et al. A
serum microRNA signature predicts tumor relapse and survival in triple-negative breast
cancer patients. Clin Cancer Res 2015; 21: 1207–1214.
124. Chen W, Cai F, Zhang B, Barekati Z, Zhong XY. The level of circulating miRNA-10b and
miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers.
Tumour Biol 2013; 34: 455–462.
125. Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as
blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer
Res 2010; 12: R90.
126. Shaker O, Maher M, Nassar Y, Morcos G, Gad Z. Role of microRNAs -29b-2, -155, -197
and -205 as diagnostic biomarkers in serum of breast cancer females. Gene 2015; 560:
77–82.
127. Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H et al. Circulating microRNA-92a and
microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer
Res Clin Oncol 2013; 139: 223–229.
128. Huo D, Clayton WM, Yoshimatsu TF, Chen J, Olopade OI. Identification of a circulating
MicroRNA signature to distinguish recurrence in breast cancer patients. Oncotarget 2016;
;7: 55231–55248.
129. Eichelser C, Flesch-Janys D, Chang-Claude J, Pantel K, Schwarzenbach H. Deregulated
serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and
miR-373 in human breast cancer development and progression. Clin Chem 2013; 59:
1489–1496.
130. Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z et al. Circulating MiR-125b as a marker
predicting chemoresistance in breast cancer. PLoS ONE 2012; 7: e34210.
131. Sun Y, Wang M, Lin G, Sun S, Li X, Qi J et al. Serum microRNA-155 as a potential
biomarker to track disease in breast cancer. PLoS ONE 2012; 7: e47003.
132. Witwer KW. Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin
Chem 2015; 61: 56–63.
133. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ. Comparing the MicroRNA
spectrum between serum and plasma. PLoS ONE 2012; 7: e41561.
134. Diener Y, Walenda T, Jost E, Brummendorf TH, Bosio A, Wagner W et al. MicroRNA
expression profiles of serum from patients before and after chemotherapy. Genomics Data
2015; 6: 125–127.
135. Hansen TF, Carlsen AL, Heegaard NH, Sorensen FB, Jakobsen A. Changes in circulating
microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment
response in patients with metastatic colorectal cancer. Br J Cancer 2015; 112: 624–629.
136. Ponomaryova AA, Morozkin ES, Rykova EY, Zaporozhchenko IA, Skvortsova TE,
Dobrodeev capital AC et al. Dynamic changes in circulating miRNA levels in response to
antitumor therapy of lung cancer. Exp Lung Res 2016; 42: 95–102.
137. Li Y, Kowdley KV. Method for microRNA isolation from clinical serum samples. Anal
Biochem 2012; 431: 69–75.
138. Mathivanan S, Lim JW, Tauro BJ, Ji H, Moritz RL, Simpson RJ. Proteomics analysis of A33
immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215
reveals a tissue-specific protein signature. Mol Cell Proteomics 2010; 9: 197–208.
139. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic
biomarkers of ovarian cancer. Gynecol Oncol 2008; 110: 13–21.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are
included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the
Creative Commons license, users will need to obtain permission from
the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2017
Circulating microRNAs in breast cancer
R Hamam et al
12
Cell Death and Disease
